PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

Dexmedetomidine Outperforms Stellate Block Plus Ketamine on Hemodynamics in Post-TBI Storming

paroxysmal sympathetic hyperactivitytraumatic brain injurystellate ganglion blockketaminedexmedetomidinebupivacainealpha-2 agonistNMDA antagonistneurocritical carerandomized controlled trialhemodynamicsICU Critical Care / ICU

Background Information

Dexmedetomidine versus ketamine in PSH management after traumatic brain injury.

Paroxysmal sympathetic hyperactivity (PSH) after traumatic brain injury can complicate recovery, requiring effective management strategies. Dexmedetomidine rapidly decreased mean arterial blood pressure compared to stellate ganglion block combined with subanesthetic ketamine, though both improved neurological outcomes equally. While dexmedetomidine offers faster hemodynamic control, both treatments are effective; the choice may depend on clinical settings or resource availability. Dexmedetomidine quickly reduces blood pressure in PSH, but both treatments aid neurological recovery post-TBI.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.

Authors: Mohamed ESAM, Kamel AAF, Mohamed AMG, Elmesallamy AEWAEA, Mohamed MG, Shaker MA, Khashaba OA, Medhat MM

Citation: Mohamed ESAM, Kamel AAF, Mohamed AMG, et al. Stellate Ganglion Block Combined With Subanesthetic Ketamine Versus Dexmedetomidine for the Management of Paroxysmal Sympathetic Hyperactivity (PSH) After Traumatic Brain Injury: A Randomized Trial. Critical care research and practice. 2026;2026:2779975. doi:10.1155/ccrp/2779975

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Founding member rate
$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.
Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.